Also listed on Facet Biotech Corporation, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends no later than Aug 29, 2029 · Low confidence
20-year base term ended May 7, 2024
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
May 7, 2004
Aug 29, 2029
May 4, 2010
This patent's term runs 844 days past its 20-year base term on prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 2 of 3 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 7, 2004, when application 10/842,011, the earliest non-provisional in its chain, was filed (this one was filed Nov 5, 2004) | May 7, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +844 days, USPTO patent term adjustment record | Aug 29, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | +1096 days, USPTO 35 U.S.C. 156 certificate | added to Aug 29, 2026: Aug 29, 2029 | High confidence |
| Fee events | No fee event states this; the fee state is read from the payments the fee record holds | In force | Medium confidence |
| Computed term end | The steps above, in order | no later than Aug 29, 2029 | Low confidence |
Partial family
| Application 10/842,011 | Abandoned not computed | not computed |
| US 7,709,610 | this patent no later than Aug 2029 | no later than Aug 2029 |
| US 8,008,450 | Term ended no later than May 2024 | no later than May 2024 |
| US 8,445,646 | Term ended no later than May 2024 | no later than May 2024 |
| US 9,175,081 | Term ended no later than May 2024 | no later than May 2024 |
| US 10,442,859 | Term ended Aug 2025 | Aug 2025 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 29, 2005 Reel 15963, frame 875 | Williams, Marna; Tso, J. Yun; Landolfi, Nicholas F.; Powers, David B; Dubridge, Robert B.; Law, Debbie; Liu, Gao | Protein Design Labs, Inc. | Assignment of Assignor's Interest |
| May 22, 2006 Reel 17655, frame 436 | Protein Design Labs, Inc. | PDL Biopharma, Inc. | Change of Name |
| Feb 27, 2009 Reel 22326, frame 412 | PDL Biopharma, Inc. | Facet Biotech Corporation | Assignment of Assignor's Interest |
| Oct 29, 2010 Reel 25217, frame 95 | Facet Biotech Corporation | Abbott Biotherapeutics Corp. | Change of Name |
| Jan 11, 2013 Reel 29612, frame 275 | Abbott Biotherapeutics Corp. | AbbVie Biotherapeutics Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Aug 29, 2029. We will not guess the cap.